<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659515</url>
  </required_header>
  <id_info>
    <org_study_id>S-11-0001</org_study_id>
    <nct_id>NCT01659515</nct_id>
  </id_info>
  <brief_title>Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria</brief_title>
  <official_title>Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meiji Seika Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uniformed Services University of the Health Sciences</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <brief_summary>
    <textblock>
      Arbekacin for the use of infection caused by multidrug-resistant organisms&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this protocol is to make arbekacin available for treatment of patients&#xD;
      with infections caused by multidrug-resistant organisms when treatment with other antibiotics&#xD;
      cannot be used due to unavailability, intolerance, contraindications, or treatment&#xD;
      non-response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Infection Due to Resistant Organism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbekacin Sulfate</intervention_name>
    <description>Intravenous arbekacin in a total daily dose of 5-7 mg/kg</description>
    <other_name>Arbekacin</other_name>
    <other_name>Habekacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is military health care beneficiary at least 18 years of age;&#xD;
&#xD;
          2. Subject is a Walter Reed National Military Medical Center patient deemed by the&#xD;
             primary medical or surgical team as having a bacterial infection of the respiratory&#xD;
             tract, bloodstream, skin, soft tissue, bone, or genitourinary tract;&#xD;
&#xD;
          3. Subject is allergic to or intolerant of antibiotics to which the infective organism is&#xD;
             susceptible; Or The use of antibiotics to which the subject's infective organism is&#xD;
             susceptible is contraindicated; Or&#xD;
&#xD;
             Subject's infective organism isolate is a multidrug-resistant (MDR) bacterium defined&#xD;
             as any of the following:&#xD;
&#xD;
               -  Gram-negative bacterium that is non-susceptible to all index antibiotics within 3&#xD;
                  or more of 6 antibiotic classes including aminoglycosides (amikacin, gentamicin,&#xD;
                  tobramycin), beta-lactam/beta-lactam inhibitor combinations&#xD;
                  (piperacillin-tazobactam, amoxicillin-clavulanate), carbapenems (imipenem,&#xD;
                  ertapenem), fluoroquinolones (ciprofloxacin, levofloxacin), cephalosporins&#xD;
                  (ceftazidime, cefepime, ceftriaxone), and sulbactam (ampicillin-sulbactam);&#xD;
&#xD;
               -  Extended Spectrum β-lactamase (ESBL) producing Gram-negative bacterium;&#xD;
&#xD;
               -  Carbapenemase resistant Enterobacteriaceae;&#xD;
&#xD;
               -  Cephalosporin resistant Klebsiella species;&#xD;
&#xD;
               -  Methicillin-resistant Staphylococcus aureus (MRSA);&#xD;
&#xD;
               -  Vancomycin resistant Enterococcus species;&#xD;
&#xD;
               -  Staphylococcus aureus that is non-susceptible to vancomycin.&#xD;
&#xD;
          4. Subject's infective organism is inhibited in vitro by arbekacin at a concentration ≤ 4&#xD;
             μg/mL;&#xD;
&#xD;
          5. Subject is able to give written or witnessed verbal informed consent [An exception&#xD;
             from the general requirements for informed consent can be made based upon the criteria&#xD;
             specified in 21 Code of Federal Regulations 50.23 (a and c)];&#xD;
&#xD;
          6. Subject has adequate venous access for intravenous administration of arbekacin.&#xD;
&#xD;
          7. Sexually active females, unless surgically sterile or at least 1 year post-menopausal,&#xD;
             must have used an effective method of avoiding pregnancy (including oral or implanted&#xD;
             contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap,&#xD;
             abstinence, use of a condom by the sexual partner, or sterile sexual partner) for at&#xD;
             least 30 days prior to receipt of arbekacin and must agree to continue using such&#xD;
             precaution for at least 30 days after last dose of arbekacin; the subject must also&#xD;
             have a negative pregnancy test within 24 hours prior to initial dose of arbekacin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a history of allergy or serious adverse reaction to aminoglycoside&#xD;
             antibiotics;&#xD;
&#xD;
          2. Subject is currently participating in another investigational new drug study.&#xD;
&#xD;
          3. Subject has a positive serum pregnancy test or is breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Michael Zapor, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Institute of Research (WRAIR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center (WRNMMC)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 3, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arbekacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

